Last reviewed · How we verify
HF50
At a glance
| Generic name | HF50 |
|---|---|
| Sponsor | HighField Biopharmaceuticals Corporation |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors (EARLY_PHASE1)
- A Relative Bioavailability Study of 50 mg Venlafaxine Hydrochloride Tablets Under Fed Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HF50 CI brief — competitive landscape report
- HF50 updates RSS · CI watch RSS
- HighField Biopharmaceuticals Corporation portfolio CI